Related Experiment Video

Updated: May 31, 2025

Partial Bile Duct Ligation in the Mouse: A Controlled Model of Localized Obstructive Cholestasis
04:38

Partial Bile Duct Ligation in the Mouse: A Controlled Model of Localized Obstructive Cholestasis

Published on: March 28, 2018

15.5K

Recent advances in the management of pediatric cholestatic liver diseases

Krupa R Mysore1, Katherine Cheng2, Lakshmi Anandini Suri3

  • 1Division of Gastroenterology, Hepatology and Nutrition, Department of Pediatrics, Texas Children's Hospital, Baylor College of Medicine, Houston, Texas, USA.

Journal of Pediatric Gastroenterology and Nutrition
|January 22, 2025
PubMed

Insights

Pediatric cholestatic liver diseases require optimized management for quality of life and disease slowing. While ileal bile acid transporter (IBAT) inhibitors show promise for symptom relief, effective disease-modifying therapies are still needed.

Area of Science:

  • Hepatology
  • Pediatric Gastroenterology
  • Rare Diseases

Background:

  • Pediatric cholestatic liver diseases are rare, with biliary atresia, Alagille syndrome (ALGS), and inherited bile acid transport disorders as common causes.
  • These conditions cause chronic or episodic cholestasis, impacting quality of life and often necessitating liver transplantation due to lack of curative therapies.

Purpose of the Study:

  • To provide an updated review on the nutritional, medical, and surgical management of pediatric cholestatic liver diseases.
  • To evaluate recent advancements, including the use of ileal bile acid transporter (IBAT) inhibitors, in managing these conditions.

Main Methods:

  • Review of current literature and prospective clinical trial data on pediatric cholestatic liver diseases.
  • Analysis of the efficacy and limitations of emerging therapies like IBAT inhibitors.

Main Results:

  • Clinical trials indicate that IBAT inhibitors can improve pruritus in conditions like ALGS and progressive familial intrahepatic cholestasis.
  • Nutritional support, medical management, and surgical interventions are crucial for improving patient quality of life and slowing disease progression.

Conclusions:

  • Optimizing management is essential for pediatric cholestatic liver diseases, addressing nutritional needs, toxicity, and quality of life.
  • Despite advancements with IBAT inhibitors for symptom control, developing therapies that halt disease progression remains a critical unmet need in pediatric liver disease management.

Keywords:
biliary atresiapediatric cholestasispediatric hepatologypruritus

More Related Videos

A Mouse Model of Chronic Liver Fibrosis for the Study of Biliary Atresia09:12

A Mouse Model of Chronic Liver Fibrosis for the Study of Biliary Atresia

Published on: February 3, 2023

2.4K
A Two-Step Method for Percutaneous Transhepatic Choledochoscopic Lithotomy03:56

A Two-Step Method for Percutaneous Transhepatic Choledochoscopic Lithotomy

Published on: September 13, 2022

2.3K

Related Concept Videos

Chronic Pancreatitis II: Collaborative Care01:29

Chronic Pancreatitis II: Collaborative Care

The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:
70
Diseases of the Liver and Gallbladder01:26

Diseases of the Liver and Gallbladder

Liver and gallbladder diseases are a significant health concern, with prominent conditions including cirrhosis, hepatitis, non-alcoholic fatty liver disease (NAFLD), and gallstones. Jaundice is a common manifestation of liver and biliary disease.
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not...
420
Esophageal Varices-II: Clinical Features and Management01:28

Esophageal Varices-II: Clinical Features and Management

Esophageal varices often manifest as gastrointestinal bleeding episodes, presenting symptoms like hematemesis (vomiting of blood), hematochezia (passing fresh blood via the rectum), and melena (black, tarry stools). Other signs can include weight loss, anorexia, abdominal discomfort, jaundice, pruritus, altered mental status, and muscle cramps.
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol...
45
Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance01:07

Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance

Drug transporters are critical in drug absorption, distribution, and excretion processes. They should be included in physiological-based pharmacokinetic (PBPK) models, which help predict human drug disposition. However, predicting this is challenging during drug development, especially when liver transport is involved. However, with a realistic representation of body transport processes, an accurate model may be possible.
A recent model describes pravastatin's hepatobiliary excretion,...
26
Acute Pancreatitis II: Clinical Manifestations and Management01:30

Acute Pancreatitis II: Clinical Manifestations and Management

Acute pancreatitis presents a complex medical emergency characterized by rapid onset inflammation of the pancreas, demanding timely diagnosis and management to prevent complications. The condition primarily manifests through severe upper abdominal pain that often radiates to the back. This pain intensifies following the consumption of fatty foods. Accompanying symptoms such as nausea, vomiting, abdominal distention, fever, dyspnea, cyanosis, and jaundice can vary in intensity but significantly...
93